Japan Lyxumia nod ups GLP-1 stakes
This article was originally published in Scrip
Sanofi's glucagon-like peptide-1 receptor agonist Lyxumia (lixisenatide; licensed from Zealand Pharma) has been approved in Japan, where it has become the first product in its class to be cleared for use in combination with basal insulin for the treatment of type 2 diabetes.
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Japan’s largest pharma company says it has seen no impact on its financial results so far from the coronavirus pandemic, with continuing growth for mainstay drugs, and raises its profit forecasts for the fiscal year on favorable one-off factors.
Roche’s Japanese affiliate says the impact of the pandemic on its second quarter was limited, but points to a more uncertain outlook for the rest of the year, during which it vows to keep focusing on innovation.